Verastem Inc
F:2VSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Verastem Inc (2VSA) under the Base Case is 12.441 EUR per share.
Compared with the current market price of 5.596 EUR, the stock appears
Undervalued by 55% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Verastem Does
Verastem is a biotechnology company focused on cancer drugs, especially medicines that target tumors driven by the RAS/MAPK signaling pathway. Its main work is to develop, test, and bring to market prescription therapies for hard-to-treat cancers, with a strong emphasis on ovarian cancer and other solid tumors. In simple terms, it is a drug maker, not a hospital or a research tools company.
- Headquarters
- United States of America US
- Employees
- 102
- IPO date
- Nov 8, 2011
Balance Sheet
Recent Events
Latest Earnings Call
Verastem advanced VS-7375 toward frontline Phase III development, continued building its CO-PACK business, and outlined a CEO transition and a priority-review NDA.
Open the earnings call- EPS
- −$0.74
- Expected
- −$0.44
- Surprise
- −68.2%
- Stock, next trading day
- −10.3%
Verastem insiders are selling within their usual range
Past 12 months
Continue 2VSA Research
Decided on Verastem? Get an email when 2VSA reaches the price you’d buy at. Free with an account.
Other Verastem listings
What is the Intrinsic Value of one 2VSA stock?
The intrinsic value for
Verastem Inc (2VSA) under the Base Case is 12.441 EUR.
Is 2VSA stock undervalued or overvalued?
Compared with the current market price of 5.596 EUR, the stock appears Undervalued by 55% .